Quick Answer
Gossamer Bio, Inc. reported Total Revenue of $48.47 million for fiscal year 2025.
Gossamer Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $48.47M -57.7% |
$114.70M | $0.00 | $0.00 | — | — |
| Revenue (ASC 606) | $48.47M -57.7% |
$114.70M | $0.00 | $0.00 | — | — |
| Net Income | -$170.37M -201.4% |
-$56.53M +68.6% |
-$179.82M +21.6% |
-$229.38M +2.0% |
-$234.00M +3.8% |
-$243.36M -35.0% |
| Diluted EPS | -$0.75 -200.0% |
-$0.25 +78.8% |
-$1.18 +56.5% |
-$2.71 +13.4% |
-$3.13 +11.8% |
-$3.55 -7.9% |
| Total Assets | $172.25M -45.4% |
$315.29M +1.1% |
$311.92M +14.5% |
$272.45M -20.7% |
$343.66M -36.3% |
$539.43M +26.4% |
| Cash and Equivalents | $37.73M -18.1% |
$46.07M +43.5% |
$32.11M -71.3% |
$111.97M -38.9% |
$183.40M -62.3% |
$486.06M +260.0% |
| Long-Term Debt | — | $0.00 -100.0% |
$814.0K -93.2% |
$11.99M -58.8% |
$29.08M +1.2% |
$28.74M +1.0% |
| Stockholders Equity | -$122.76M -516.2% |
$29.49M -53.0% |
$62.77M +419.7% |
$12.08M -90.1% |
$121.46M -62.1% |
$320.68M -9.0% |
| Operating Income | -$170.73M -184.9% |
-$59.92M +67.4% |
-$183.76M +15.9% |
-$218.59M -1.1% |
-$216.12M +7.6% |
-$233.96M -25.7% |
| Shares Outstanding | 233.68M +3.1% |
226.60M +0.5% |
225.41M +138.7% |
94.42M +24.6% |
75.75M +2.5% |
73.87M +19.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.29M | +40.2% | +15.7% |
| Revenue (ASC 606) | September 30, 2025 | $13.29M | +40.2% | +15.7% |
| Net Income | September 30, 2025 | -$48.22M | -56.5% | -26.0% |
| Diluted EPS | September 30, 2025 | -$0.21 | -50.0% | -23.5% |
| Total Assets | September 30, 2025 | $208.82M | -40.5% | -13.3% |
| Cash and Equivalents | September 30, 2025 | $8.93M | -68.6% | -66.0% |
| Long-Term Debt | September 30, 2024 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | -$82.33M | -252.1% | -78.6% |
| Operating Income | September 30, 2025 | -$49.11M | -44.8% | -26.7% |
| Shares Outstanding | September 30, 2025 | 231.31M | +2.1% | +1.8% |
- Gossamer Bio, Inc. reported Total Revenue of $48.47 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -57.7% in Total Revenue compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Revenue (ASC 606) of $48.47 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -57.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Net Income of -$170.37 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -201.4% in Net Income compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Diluted EPS of $0.75 per share (loss) for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -200.0% in Diluted EPS compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Total Assets of $172.25 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -45.4% in Total Assets compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Cash and Equivalents of $37.73 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -18.1% in Cash and Equivalents compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
- Gossamer Bio, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Stockholders Equity of -$122.76 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -516.2% in Stockholders Equity compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Operating Income of -$170.73 million for fiscal year 2025.
- Gossamer Bio, Inc. showed a decrease of -184.9% in Operating Income compared to the prior fiscal year.
- Gossamer Bio, Inc. reported Shares Outstanding of 233.68 million shares for fiscal year 2025.
- Gossamer Bio, Inc. showed an increase of +3.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: